Cancer Therapeutics Based on Novel Cyclopamine Analogs
These compounds may be useful for treating primary cancer, or for preventing metastatic disease in breast, lung, pancreatic, prostate, and other cancers. Unlike the parent compound, cyclopamine, and its previously-described derivatives, these steroid-derived analogs developed are simple to synthesize. They retain the effectiveness of cyclopamine as an anti-cancer agent.
PCT Application No. PCT/US2008/081704 (WO 2009/058945, published 05/07/2009); a U.S. application has been filed.
Wistar is seeking to collaborate with a corporate partner to use this technology to develop small molecule cancer therapies. An exclusive license or sponsored research to further develop the technology would be considered.